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Background: This study assessed whether i.v. sildenafil citrate prevented acute kidney injury in at-risk patients un-
dergoing cardiac surgery with cardiopulmonary bypass.
Methods: In a double-blind RCT, adults at increased risk of acute kidney injury undergoing cardiac surgery in a single UK
tertiary centre were randomised to receive sildenafil citrate 12.5 mg kg1 i.v. over 150 min or dextrose 5% at the
commencement of surgery. The primary outcome was serum creatinine measured at six post-randomisation time
points. The primary analysis used a linear mixed-effects model adjusted for the stratification variables, baseline esti-
mated glomerular filtration rate, and surgical procedure. Secondary outcomes considered clinical events and potential
disease mechanisms. Effect estimates were expressed as mean differences (MDs) or odds ratios with 95% confidence
intervals.
Results: The analysis population comprised eligible randomised patients that underwent valve surgery or combined
coronary artery bypass graft and valve surgery, with cardiopulmonary bypass, between May 2015 and June 2018. There
were 60 subjects in the sildenafil group and 69 in the placebo control group. The difference between groups in creatinine
concentration was not statistically significant (MD: 0.88 mmol L1 [e5.82, 7.59]). There was a statistically significant in-
crease in multiple organ dysfunction scores in the sildenafil group (MD: 0.54 [0.02, 1.07]; P¼0.044). Secondary outcomes,
and biomarkers of kidney injury, endothelial function, and inflammatory cell activation, were not significantly different
between the groups.
Conclusions: These results do not support the use of i.v. sildenafil citrate for kidney protection in adult cardiac surgery.
Clinical trial registration: ISRCTN18386427.
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Editor’s key points
 Acute kidney injury is common after cardiac surgery.
 Intravenous sildenafil has been shown to decrease
kidney injury after cardiac surgery in a porcine model.
 This clinical trial in human cardiac surgery patients
evaluated the effect of i.v. sildenafil on various surro-
gate markers of renal injury, inflammation, and organ
damage; no meaningful beneficial effect was found.
 Intravenous sildenafil is unlikely to be beneficial for
this indication, and larger trials are not warranted
based on the findings of this study.
694 - Kumar et al.Acute kidney injury (AKI) occurs in up to one-third of all pa-
tients after cardiac surgery. It is characterised by an acute
decline in kidney function as determined by elevations in
serum creatinine, and is associated with significant increases
in postoperative complications and an almost four-fold in-
crease in the risk of postoperative death.1,2 Our understanding
of the underlying processes is poor and there are no effective
preventive measures.3 Experimental studies have demon-
strated that preservation of endogenous nitric oxide (NO)
bioavailability is renoprotective in response to a variety of
injurious stimuli.4,5 Endogenous NO activity is increased by
the administration of the phosphodiesterase (PDE) type 5 in-
hibitor sildenafil citrate. This is used clinically in the treatment
of erectile dysfunction (Viagra®; Pfizer, New York, NY, USA)
and more recently as an i.v. formulation (Revatio®; Pfizer) for
pulmonary hypertension and acute right ventricular failure.6,7
We have shown that i.v. sildenafil prevents post-
cardiopulmonary bypass (CPB) AKI in a preclinical swine
model.8 We have also shown that sildenafil administered at a
dose of 12.5 mg to adults during cardiac surgery is well toler-
ated and achieves plasma concentrations known to be clini-
cally effective in some settings.9 This Phase IIb efficacy trial
tested the hypothesis that the administration of i.v. sildenafil
would reduce postoperative AKI in cardiac surgery patients
identified before operation as being at increased risk of
developing kidney injury.Methods
Trial design/participants
The effect of sildenafil (REVATIO®) on post-cardiac surgery
acute kidney injury: a randomised, placebo-controlled clinical
trial: the REVAKI-2 trial (registration ISRCTN18386427 on
October 1, 2015) was a parallel group RCT conducted at a single
tertiary cardiac surgery centre in the UK. Male and female
adult patients undergoing coronary artery bypass graft (CABG),
open valve, or combined CABG and open-valve surgery who
were at increased risk of developing AKI, as determined by a
modified AKI risk score1 (a predicted risk score of 20% equates
to a positive predicted value for developing AKI of >55%) were
eligible. Exclusions, listed in the Supplementary material,
included patientswith pre-existing AKI, sepsis, Stage 5 chronic
kidney disease, severe hepatic impairment, allergy to PDE
Type 5 inhibitors, or recent treatment with cytochrome P450
3A4 inhibitors or guanylate cyclase stimulators. Participants
provided written informed consent before operation. Theallocated interventionwas administered at skin incision at the
start of surgery. Participants were followed-up until discharge
and at 6 weeks and 3 months after randomisation. The trial
complied with the Declaration of Helsinki. The Yorkshire and
The Humber Leeds East Research Ethics Committee approved
the study (reference 15/YH/0489) on December 7, 2015. A
detailed protocol has been reported elsewhere.10 The Univer-
sity of Leicester was the trial sponsor. Changes to the trial after
commencement are described in the Supplementary material.Randomisation and blinding
Participants were randomly assigned to either sildenafil or
placebo in a 1:1 ratio, using an internet-based randomisation
system (Sealed Envelope Ltd, a Medicines and Healthcare
Products Regulatory Agency recognised facility) with con-
cealed allocation. Randomisation was stratified by (i) type of
procedure: CABG, valve, CABG and valve, and other; and (ii)
baseline estimated glomerular filtration rate (eGFR): <60, 60.
Randomisation occurred before operation after written
informed consent was given and eligibility confirmed and as
close to the scheduled surgery time as possible. Patients, re-
searchers, and clinical staff were blinded to group allocation.Interventions
Sildenafil citrate 12.5 mg in dextrose 5% (65 ml) i.v. over 150
min starting at the time of skin incision. In the placebo group,
the same volume of a dextrose solution 5% was administered
over 150 min. Trial interventions were administered via clear
syringes marked only with the participant’s trial number and
the label REVAKI-2 trial drug. Details of perioperative care
protocols, monitoring of protocol compliance, blinding of
clinical staff, and other steps to mitigate bias are described in
the Supplementary material.Outcomes
Timings of outcome assessment are listed in Supplementary
Table S3.Primary outcome
The primary outcome for the trial was serum creatinine con-
centration over time in both groups. The time points included
were pre-operation (baseline); on arrival to cardiac ICU (CICU)
after surgery; and at 6e12, 24, 48, 72, and 96 h post-surgery.Secondary outcomes
Secondary outcomes are listed in Supplementary Table S1.
Briefly, these included serial measures of the eGFR and mul-
tiple organ dysfunction scores (MODS; range: 0e24, with
higher scores indicating more severe organ dysfunction, as
defined in a recent trial)11 from baseline to 96 h post-surgery,
with a final serum creatinine sample for estimation of eGFR
at 6 weeks; consensus clinical definitions of acute kidney,
lung, liver, gut, brain, and myocardial injury; and sepsis,
death, and a composite of these outcomes. Biomarkers of the
inflammatory response (serum interleukin [IL]-6, IL-8, and IL-
10) and myocardial injury (Serum troponin I), and urine bio-
markers of inflammation (neutrophil gelatinase-associated
lipocalcin [NGAL]) and injury (tissue inhibitor metal-
loproteinase-2* insulin-like growth factor [IGF]-binding
protein-7 [Timp2*IGFBP7]) were measured in serial serum and
Screened paƟents (n=1062)
Eligible paƟents approached (n=309)
PaƟents excluded (n=753)
Cardiac surgery paƟents (<18 yr) undergoing cardiac surgery with CPB and cardioplegic arrest
Emergency or salvage procedure
EjecƟon fracƟon <20%
CKD Stage 5 or RRT
PaƟents with a pre-exisƟng sepsis or organ injury within 5 days of surgery
AdministraƟon of potent CYP3A4 inhibitors within 1 month before study parƟcipaƟon
AdministraƟon of nitrate medicines or nitric oxide donors within 24 h of surgery
PaƟents allergic to sildenafil or any other phosphodiesterase (PDE)-5 inhibitor
Any ongoing malignancy or prior malignancy that currently requires treatment
PaƟents who are parƟcipaƟng in another intervenƟonal clinical study
PaƟents who have loss of vision in one eye as a result of NAION, regardless of whether it is connected to previous PDE-5 
inhibitor exposure
Risk of pregnancy
Severe hepaƟc impairment
Severe hypotension on the day before surgery
AdministraƟon of the guanylate cyclase sƟmulators
Unable, in the opinion of the invesƟgator, or unwilling to give informed consent
Randomised paƟents (n=129)
Allocated to sildenafil (n=60)
Received allocaƟon (n=60)
Did not receive allocaƟon (n=0)
Allocated to placebo (n=69)
Received allocaƟon (n=69)
Did not receive allocaƟon (n=1)
PaƟents that withdrew 
before surgery (n=4):
- InvesƟgator decision
Placebo (n=3)
IntervenƟon (n=2)
PaƟents declined (n=180)
Underwent surgery (n=58)
Follow-up at 3 months
(n=55; 91.7%)
Underwent Surgery (n=67)
Follow-up at 3 months
(n=62; 89.9%)
Excluded from primary analysis 
of primary outcome 
(n=1; 1.5%)
Reasons for exclusion:
Baseline eGFR missing (n=1)
Excluded from primary analysis 
of primary outcome 
(n=1; 1.7%)
Reasons for exclusion:
Baseline eGFR missing (n=1)
Major protocol deviaƟons 
(n=5)
- Missing more than three serum 
creaƟnine follow-up values in the 
first 5 days
Placebo (n=2)
IntervenƟon (n=2)
- Did not receive 
intervenƟon/placebo
Placebo (n=1)
PaƟents that withdrew aŌer 
surgery (n=8)
- PaƟent died
Placebo (n=3)
IntervenƟon (n=1)
- No data at 3 months
Placebo (n=2)
IntervenƟon (n=2)  
Fig. 1. Flow of participants showing eligibility, recruitment, protocol deviations, withdrawals, and loss to follow-up in the REVAKI-2 trial.
CKD, chronic kidney disease; CYP3A4, cytochrome P450 3A4; eGFR, estimated glomerular filtration rate; NAION, non-arteritic anterior
ischaemic optic neuropathy; RRT, renal replacement therapy.
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Table 1 Participant characteristics and past history. CCS, Canadian Cardiovascular Society; CVA, cerebrovascular accident; CYP3A4,
cytochrome P450 3A4; IQR, inter-quartile range; LV, left ventricular; NYHA, New York Heart Association; SD, standard deviation; TIA,
transient ischaemic attack.
Characteristic Placebo (n¼67) Sildenafil (n¼58) Overall (n¼125)
n % n % n %
Demography
Sex (female) 10 14.93 14 24.14 24 19.2
Age (yr) (mean, range) 72 (52, 88) 72 (54, 88) 72 (52, 88)
BMI (median, IQR) 30.9 (26.6, 36.3) 31.1 (27.7, 35.4) 31 (27.1, 35.7)
AKI risk score (median, IQR) 30.1 (25.8, 40) 29.6 (24.5, 38) 29.95 (25.6, 39.8)
Cardiac disease
NYHA class
I 7 10.45 7 12.07 14 11.20
II 50 74.63 37 63.79 87 69.60
III 8 11.94 11 18.97 19 15.20
IV 1 1.49 0 0.00 1 0.80
Missing 1 1.49 3 5.17 4 3.20
CCS class
Asymptomatic 21 31.34 19 32.76 40 32.00
I 27 40.30 19 32.76 46 36.80
II 15 22.39 15 25.86 30 24.00
III 1 1.49 3 5.17 4 3.20
IV 1 1.49 0 0.00 1 0.80
Missing 2 2.99 2 3.45 4 3.20
LV function
Good (>49%) 47 70.15 37 63.79 84 67.20
Moderate (30e49%) 16 23.88 19 32.76 35 28.00
Poor (<30%) 3 4.48 2 3.45 5 4.00
Missing 1 1.49 0 0.00 1 0.80
>50% disease in left main stem 4 5.97 5 8.62 9 7.20
50% disease in left main stem 63 94.03 51 87.93 114 91.20
Missing 0 0.00 2 3.45 2 1.60
Coronary disease
None 24 35.82 12 20.69 36 28.80
Number of vessels
Single 14 20.90 12 20.69 26 20.80
Double 5 7.46 12 20.69 17 13.60
Triple 23 34.33 20 34.48 43 34.40
Missing 1 1.49 2 3.45 2 2.40
Blood and urine results
Haemoglobin (mean, sd) 128.8 20.1 129.6 17.5 129.2 18.8
Haematocrit (mean, sd) 37.8 5.5 38.3 4.8 38.0 5.2
Platelets (median, IQR) 203 (168, 245) 194 (164.5, 237.5) 196 (166, 238)
Serum creatinine (median, IQR) 89 (73, 103) 92 (79, 110) 90 (75, 106)
Estimated glomerular filtration rate (mean, sd) 75.6 23.6 70.7 20.1 73.3 22.1
Medical history
Diabetes mellitus
Yes 24 35.82 26 44.83 50 40.00
No 42 62.69 32 55.17 74 59.20
Missing 1 1.49 0 0.00 1 0.80
Diet
Yes 4 5.97 3 5.17 7 5.60
Not applicable 43 64.18 32 55.17 75 60.00
Missing 20 29.85 23 39.66 43 34.40
Oral
Yes 14 20.90 17 29.31 31 24.80
Not applicable 43 64.18 32 55.17 75 60.00
Missing 10 14.93 9 15.52 19 15.20
Insulin
Yes 7 10.45 7 12.07 14 11.20
Not applicable 43 64.18 32 55.17 75 60.00
Missing 17 25.37 19 32.76 36 28.80
Continued
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Table 1 Continued
Characteristic Placebo (n¼67) Sildenafil (n¼58) Overall (n¼125)
n % n % n %
Pacemaker
Yes 4 5.97 5 8.62 9 7.20
No 62 92.54 53 91.38 115 92.00
Missing 1 1.49 0 0.00 1 0.80
Temporary
Yes 0 0.00 0 0.00 0 0.00
Permanent
Yes 1 1.49 5 8.62 6 4.80
Not applicable 63 94.03 53 91.38 116 92.80
Missing 3 4.48 0 0.00 3 2.40
CVA or TIA
Yes 2 2.99 1 1.72 3 2.40
No 64 95.52 56 96.55 120 96.00
Missing 1 1.49 1 1.72 2 1.60
Smoking status
Current 5 7.46 2 3.45 7 5.60
Never 15 22.39 17 29.31 32 25.60
Ex (>1 month) 46 68.66 38 65.52 84 67.20
Missing 1 1.49 1 1.72 2 1.60
Redo cardiac surgery
Yes 2 2.99 4 6.90 6 4.80
No 65 97.01 54 93.10 119 95.20
Myocardial infarction
Yes 8 11.94 12 20.69 20 16.00
No 58 86.57 46 79.31 104 83.20
Missing 1 1.49 0 0.00 1 0.80
Medications
Nitrates until operating theatre
Yes 2 2.99 3 5.17 5 4.00
No 4 5.97 3 5.17 7 5.60
Not applicable 61 91.04 52 89.66 113 90.40
Clexane® within 12 h before operation
Yes 0 0.00 0 0.00 0 0.00
No 6 8.96 6 10.34 12 9.60
Not applicable 61 91.04 52 89.66 113 90.40
Anti-platelet agents and dual anti-platelet for 5 days before operation
Yes 5 7.46 2 3.45 7 5.60
No 1 1.49 4 6.90 5 4.00
Not applicable 61 91.04 52 89.66 113 90.40
CYP3A4 inhibitors within last month
Yes 0 0.00 0 0.00 0 0.00
No 6 8.96 6 10.34 12 9.60
Not applicable 61 91.04 52 89.66 113 90.40
Sildenafil for renoprotection in cardiac surgery - 697urine samples, as described in Supplementary Table S2.
Adverse events were reported descriptively. The results of a
pre-specified mechanistic analysis of platelet leucocyte and
endothelial activation will be reported separately.Sample size
On the basis that the observed standard deviation (SD) for
serum creatinine values from the MaRACAS study (an obser-
vational case control study to identify the role of microvesicle
and microvesicle derived micro-RNA in post cardiac surgery
acute kidney injury) (NCT02315183) was 37 mmol L1, and the
mean observed correlation between baseline and five post-
surgery measures of 0.84, we estimated that a sample size of
56 patients per group would have a 90% power to detect a
mean difference of 10 mmol L1 for serum creatinine values
between treatment and placebo groups with an a value of 0.05,
after adjustment for baseline values. We aimed to recruit 126patients (63 per group), anticipating that 10% of patients would
be treated outside of the protocol, withdrawn, or lost to follow-
up. This sample size would also allow us to detect an absolute
reduction in the frequency of AKI from 65% to 40%with an 80%
power and 5% significance (two-tailed).Statistical analysis
The primary analysis population included all randomised
participants, excluding patients who did not undergo surgery
or provide baseline eGFR. Outcomes are reported by intention
to treat andwere directed by a pre-specified statistical analysis
plan (appended to the Supplementary material). Continuous
variables are summarised using the mean and SD (or median
and inter-quartile range [IQR] if the distribution is skewed),
and categorical data are summarised as a number and per-
centage. The primary analysis of the primary outcome
compared all available data with no imputation using a linear
698 - Kumar et al.mixed-effects model adjusted for the stratification variables,
baseline eGFR, and surgical procedure. Treatment effect was
estimated with placebo as the reference group, and reported
with a 95% confidence interval. A likelihood ratio test was used
to determine statistical significance, and two-tailed P-values
<0.05 were considered statistically significant. The overall
treatment effect for the primary outcome was estimated
across the post-surgery time points with adjustment for
baseline value. Amodel with time*treatment interaction effect
estimate was also fitted. Significant differences either in the
overall effect or for individual time points were considered
evidence of a treatment effect. Subgroup analyses considered
the interaction between the treatment effect and stratification
variables.
Analyses of secondary outcomes were carried out using
linear mixed-effects models (for continuous variables that
were measured at multiple time points), linear regression
models (for continuous variables with a single measure), lo-
gistic models (binary variables), or Cox proportional-hazards
models (time-to-event variables), as described previously
(adjusted for the stratification variables, baseline eGFR, and
surgical procedure). All analyses were performed in Stata
version 15.0 (StataCorp LP, College Station, TX, USA).Results
Trial cohort and patient flows
The flow of patients through the trial is shown in Fig 1. There
were 129 patients recruited and randomised between
September 2015 and September 2018, which made up the
analysis population, 60 of whom were allocated to sildenafil
and 69 to placebo. Of the 129 randomised patients, four pa-
tients did not undergo surgery and four patients died before
hospital discharge. Follow-up was complete for 117 patients
(93.6%) at 3months. Details of patient withdrawals are listed in
Supplementary Table S3.Table 2 Primary analysis of primary outcome. All treatment estima
expressed as median (inter-quartile range [IQR]). Number of individu
overall: 123; placebo: 66; sildenafil: 57. CICU, cardiac ICU.
Analysis Randomised to placebo
(n¼67)
Randomised t
(n¼58)
Median
(mmol L¡1)
(IQR)
(mmol L¡1)
Median
(mmol L¡1)
Primary intention to treat
Baseline 89 (73 103) 92
CICU 91.5 (80 112) 95.5
6e12 h 101 (84 127) 104.5
24 h 99 (79 127) 106
48 h 100 (82 139) 107.5
72 h 96.5 (76 117) 108
96 h 97 (78 112) 110
Intervention (sildenafil)Participant characteristics
Baseline patient, clinical, and operative characteristics were
similar in the two groups (Table 1 and Supplementary
Table S4). The median AKI risk score was 29.6 (IQR: 24.5e38)
in the sildenafil group and 30.1 (IQR: 25.8e40) in the placebo
group. The median age of participants was 72 yr (IQR: 52e88)
and 81% were males. Overall, 42 (33.60%) participants were
listed for CABG surgery, 39 (31.20%) for valve surgery, and 44
(35.20%) were listed for combined CABG and valve surgery or
other. At baseline, the mean eGFR was 70.7 ml min1 m2
(1.73)2 in the sildenafil group and 75.6 ml min1 m2 (23.6) in
the placebo group. By chance, a higher proportion of partici-
pants in Sildenafil group 4 (6.90%) underwent redo surgery vs
Placebo group 2 (2.99%). This was reflected in longer bypass
(sildenafil median: 1.76 h [1.36e2.17] vs placebo median: 1.58 h
[1.17e2.03]) and cross-clamp times (sildenafil median: 1.19 h
[0.82e1.57] vs placebo median: 1.03 h [0.75e1.27]).Measures of process
Two patients in the placebo group had the infusion stopped
prematurely because of hypotension. One participant in the
intervention group was found ineligible intraoperatively
(ejection fraction <30%) and did not receive the allocated
treatment (Supplementary Table S5). Diastolic, systolic, and
mean arterial blood pressure; haematocrit; blood loss; trans-
fusion; and change in body weight between baseline and 3
days post-surgery were similar in the sildenafil and placebo
groups (Supplementary Fig. S1 and Table S4). The rates of
hypotension requiring treatment with vasopressors were
similar (30 [52%] sildenafil vs 32 [47%] placebo). There were no
anaphylactic reactions to the study medication. All partici-
pants were alive at the end of the surgery.Primary outcome
Table 2 and Fig 2a show the results of the analyses of the
primary outcome. For the primary intention-to-treat analysis,
sildenafil did not reduce serum creatinine up to 96 h after
surgery (mean difference: 0.88 mmol L1 [e5.82 to 7.59];tes are reported with adjustment for baseline values. Raw data
als contributing to each analysis by treatment group and overall:
o sildenafil Time effect
(IQR)
(mmol L¡1)
Adjusted mean
difference (95%
confidence intervals)
P-value
(79 110)
(79 118) Reference group
(84 129) 8.16 (3.32, 13.00) 0.001
(87 138) 13.19 (8.36, 18.01) <0.001
(86 153) 18.88 (14.05, 23.7) <0.001
(88 137) 12.04 (6.96, 17.13) <0.001
(89 131) 6.95 (1.84, 12.06) 0.008
Treatment effect
Adjusted mean difference
(95% confidence interval)
P-value
0.88 (e5.82, 7.59) 0.797
Fig. 2. (a) Serum creatinine values. Data expressed as mean (standard deviation [SD]). (b) Multiple organ dysfunction scores. Data expressed
as (SD). (c) Serum troponin. Data expressed as mean (SD). CI, confidence interval; CICU, cardiac ICU.
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analyses indicated a treatment effect of sildenafil. A post hoc
sensitivity analysis that excluded patients undergoing redo
procedures did not demonstrate a treatment effect.Secondary outcomes
Figure 2, Supplementary Table S7, and Figures S2 and S3 show
the results of the analyses of secondary outcomes. There was
no treatment effect for sildenafil on eGFR up to 6 weeks post-
surgery. MODS (scale: 0e24) were higher in the sildenafil
group (mean difference: 0.54 [0.02e1.07]; P¼0.044). The com-
posite outcome of sepsis; low cardiac output; and lung, liver,
brain, or gut injury was higher in the sildenafil group, but this
was not statistically significant (odds ratio: 3.19 [0.82e12.36];
P¼0.094). Time to extubation (hazard ratio [HR]: 0.80
[0.55e1.17]), CICU discharge (HR: 1.15 [0.79e1.68]), and
discharge from the hospital unit (HR: 0.98 [0.68e1.42]) were
similar. The groups were similar with respect to biomarker
concentrations for inflammation (IL-6, IL-8, and IL-10) and
kidney injury (urine NGAL and Timp2*IGFBP7) (Supplementary
Table S12). Serum troponin was higher in the sildenafil group,
but this was not statistically significantly different (mean dif-
ference: 21 503 mmol L1 [e3557 to 46 564]; P¼0.091) (Fig 2c). Thetime to resolution of arterial hyperlactatemia (>2.0 mM) was
longer in the sildenafil arm (median: 3 h [1.4e13.27] vs placebo
median: 1.67 h [1.23e9.8]). Serious expected adverse events to
3 months were similar in the groups (Supplementary
Table S13).Discussion
Main findings
The results of the REVAKI-2 trial do not support the hypothesis
that sildenafil citrate reduces the severity of post-cardiac
surgery AKI. Unexpectedly, sildenafil increased MODS rela-
tive to placebo. This was not reflected by significant differ-
ences in clinical outcomes or in serum or urine biomarkers of
kidney and myocardial injury.Strengths and limitations
The REVAKI-2 trial selected an enriched cohort of patients at
increased risk of AKI; 48% of participants developed AKI in the
placebo group, although this was less than expected. The trial
was double blinded with concealed allocation, detailed docu-
mentation of process, objective ascertainment of outcomes,
700 - Kumar et al.and very low levels of attrition. It evaluated, for the first time,
an i.v. sildenafil dose with documented pharmacokinetics that
aimed to prevent the early phase reduction in endogenous NO
bioactivity through therapeutic plasma concentrations of sil-
denafil and its active metabolite desmethylsildenafil intra-
operatively, and in the immediate postoperative period. The
short context-sensitive half-time of these substances was
thought to minimise augmentation of late NO-mediated
oxidative stress that has been documented in animal models
of AKI4,12 and as suggested by elevated NO bioavailability at 48
h post-surgery in the current trial. The trial used detailed an-
alyses of the primary outcome and complementary clinical
measures and biomarkers of injury and dysfunction in mul-
tiple organ systems. The principal limitation of the trial was
the use of serum creatinine as the primary outcome. The
limited sensitivity and specificity of this biomarker for AKI are
well recognised. This is offset by the clinical applicability of
changes in serum creatinine in current consensus definitions
of AKI13 and the ease, accuracy, and reproducibility of its
measurement. Combined with similar values for two putative
urine biomarkers of AKI (NGAL and Timp2*IGFBP7), we
conclude that sildenafil is very unlikely to have substantial
renoprotective effects in cardiac surgery patients. Another
limitation is that baseline eGFR was slightly lower and the
proportion of patients undergoing redo surgery was higher in
the sildenafil group. However, the pre-specified sensitivity
analysis, stratified by eGFR at baseline and a post hoc subgroup
analysis restricted to those patients who underwent first time
cardiac surgery, did not demonstrate any treatment effect,
supporting our overall conclusion.Clinical relevance
The trial has two novel findings: (i) the intervention was
designed based on findings in a porcine model of post-CPB, in
which AKI is characterised by alterations in NO activity and in
which multiple interventions, including sildenafil, that target
these processes have been shown to be renoprotective.8,14
Plasma sildenafil concentrations that were therapeutic in the
porcine model and are effective in other clinical settings9 had
no treatment effect in adult cardiac surgery patients. In a
younger cohort (median age: 48 yr) undergoing surgery for
rheumatic valve disease, Lei and colleagues15 demonstrated
that NO added to the CPB circuit or inhalational gases for up to
24 h post-surgery significantly reduced AKI. This effect was
attributed to the quenching of plasma cell-free haemoglobin
released during CPB by NO, an effect that may not be repro-
duced by PDE inhibition. Conversely, atrial natriuretic peptide
(ANP), which acts in part via PDE inhibition, is renoprotective in
adults undergoing cardiac surgery when administered for up to
several days post-surgery.16,17 A longer duration of sildenafil
treatment may have elicited a different result, or other pleio-
tropic effects of ANPmay underlie these observations. (ii)MODS
were higher in the sildenafil group. The effect size was small
and less than the minimum clinically important difference for
MODS specified in a previous trial.11 The risk of over-
interpretation of this small and probably clinically non-
significant difference notwithstanding it is noteworthy that
the direction of the treatment effect was driven predominantly
by differences in serum bilirubin values. The treatment effects
for serum troponin values were also in the direction of injury,
similar to the results of an RCT of pre-surgery oral sildenafil in
children undergoing cardiac surgery.18 These findings are at
odds with preclinical studies indicating a cardioprotectiveeffect of sildenafil in ischaemiaereperfusion injury.19 This po-
tential safety signal of sildenafil requires further study.Conclusions
Wedid not demonstrate a renoprotective effect for i.v. sildenafil
in adult cardiac surgery patients at increased risk of AKI.Authors’ contributions
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